Home » Stocks » PFE

Pfizer Inc. (PFE)

Stock Price: $40.11 USD 0.53 (1.33%)
Updated May 10, 2021 2:27 PM EDT - Market open
Market Cap 220.78B
Revenue (ttm) 41.91B
Net Income (ttm) 9.62B
Shares Out 5.56B
EPS (ttm) 1.97
PE Ratio 20.32
Forward PE 12.53
Dividend $1.53
Dividend Yield 3.81%
Trading Day May 10
Last Price $40.11
Previous Close $39.58
Change ($) 0.53
Change (%) 1.33%
Day's Open 39.95
Day's Range 39.78 - 40.28
Day's Volume 17,701,640
52-Week Range 30.35 - 42.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Pfizer begins process of seeking full U.S. vaccine approval: RPT

YouTube video

Yahoo Finance's Anjalee Khemlani reports on Pfizer pharmaceutical company seeking full approval in the United States. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://yo...

Other stocks mentioned: BNTX
1 day ago - Yahoo Finance

Moderna and Pfizer vaccines show defense against variants

YouTube video

Associate Faculty Director at the Harvard Global Health Institute Dr. Ingrid Katz joined Yahoo Finance Live to break down the latest news on vaccines as Pfizer and Biontech seek full FDA approval Watch ...

Other stocks mentioned: MRNA
1 day ago - Yahoo Finance

Strong growth in revenue and earnings wasn't the only story in the company's latest quarterly update.

2 days ago - The Motley Fool

Both big pharmaceutical companies have a lot to offer income investors.

Other stocks mentioned: ABBV
2 days ago - The Motley Fool

The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.

Other stocks mentioned: AZN, BBH, BTEC, FBT, IBB, JNJ, MRNA ...
2 days ago - Zacks Investment Research

Moderna and Pfizer vaccines show defense against variants

YouTube video

Associate Faculty Director at the Harvard Global Health Institute Dr. Ingrid Katz joined Yahoo Finance Live to break down the latest news on vaccines as Pfizer and Biontech seek full FDA approval. Watch...

Other stocks mentioned: MRNA
2 days ago - Yahoo Finance

European Medical Agency (EMA) is reviewing reports of a rare nerve-degenerating disorder in people who received AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine, raising new questions about potential si...

Other stocks mentioned: AZN
2 days ago - Benzinga

Pfizer's CEO said the waiver proposal "will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine.'

Other stocks mentioned: BNTX
2 days ago - CNBC

BioNTech and Pfizer announced a filing for full FDA approval of their COVID-19 vaccine.

Other stocks mentioned: BNTX
2 days ago - The Motley Fool

Pfizer and BioNTech have submitted an application for full FDA approval of their COVID-19 vaccine.

Other stocks mentioned: BNTX
3 days ago - The Motley Fool

PFE vs. NVO: Which Stock Is the Better Value Option?

3 days ago - Zacks Investment Research

Pfizer began applying for full approval on Friday, a process that could take months.

Other stocks mentioned: BNTX
3 days ago - Forbes

Pfizer and BioNTech asked for full Food and Drug Administration approval of their Covid vaccine on Friday, leading BioNTech stock to pop. That followed patent questions that hurt shares.

Other stocks mentioned: BNTX
3 days ago - Investors Business Daily

Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) have started the process to seek full approval from the U.S. Food and Drug Administration (FDA) for a COVID-19 vaccine. What Happened: The co...

Other stocks mentioned: BNTX
3 days ago - Benzinga

It's currently being administered in the US under an emergency use authorization.

Other stocks mentioned: BNTX
3 days ago - CNET

The companies are the first COVID vaccine makers in the nation to apply for full approval, which would allow Pfizer to market the vaccine directly to consumers.

Other stocks mentioned: BNTX
3 days ago - New York Post

The Pfizer shot was the first Covid-19 vaccine to be approved under an emergency use authorization in December.

Other stocks mentioned: BNTX
3 days ago - Forbes

This strong performance can be attributed to a very high demand for Pfizer's Covid-19 vaccine, which garnered $3.5 billion in Q1 sales. While the company also revised its full-year 2021 EPS guidance upw...

3 days ago - Forbes

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application (BLA) with the U.S. Food and Drug Adm...

Other stocks mentioned: BNTX
3 days ago - Business Wire

It could determine the future success of the company's COVID-19 vaccine.

3 days ago - The Motley Fool

Oppenheimer health care analyst on whether vaccine makers should lose sleep over patent waivers

YouTube video

Hartaj Singh, Oppenheimer & Co, on Covid vaccine makers under pressure as the patent waiver conversation continues. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Pete Najarian, Jeff Mil...

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, NVAX
3 days ago - CNBC Television

Mizuho Securities' Vamil Divan expresses concern about the company's post-coronavirus future.

3 days ago - The Motley Fool

Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.

Other stocks mentioned: BNTX, JNJ, MRNA, NVAX
3 days ago - CNBC

12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.

Other stocks mentioned: AREC, BKLLF, BLONF, GRSLF, HLRTF, MBII, MRNA ...
4 days ago - Proactive Investors

U.S. backs COVID-19 vaccine patent waiver

YouTube video

Yahoo Finance's Brian Sozzi, Myles Udland, Julie Hyman, and Anjalee Khemlani discuss what the vaccine patent waiver means for Moderna's business.

Other stocks mentioned: BNTX, JNJ, MRNA, NVAX
4 days ago - Yahoo Finance

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are donating doses of their COVID-19 vaccine to athletes participating in this summer's Olympic and Paralympic Games in Tokyo. What Happened: The p...

Other stocks mentioned: BNTX
4 days ago - Benzinga

The US has backed a proposal first put forward by India and South Africa for a temporary waiver on COVID-19 vaccine patents. “The administration believes strongly in intellectual property protections, b...

Other stocks mentioned: MRNA
4 days ago - Proactive Investors

Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) had a double dose of good news regarding their COVID-19 vaccines. Moderna said that its tweaked jab was successful in neutralising the South African ...

Other stocks mentioned: BNTX, MRNA
4 days ago - Proactive Investors

The Biden administration is backing international plans to suspend intellectual property protections.

Other stocks mentioned: BNTX, MRNA
4 days ago - Forbes

If enacted, such a move would hit the smaller vaccine makers particularly hard.

Other stocks mentioned: BNTX, JNJ, MRNA
4 days ago - The Motley Fool

Vaccine makers sink as Biden considers waving patents

YouTube video

Brent Saunders, former Allergan CEO, on who will make the vaccine next time. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Nadine Terman.

Other stocks mentioned: BNTX, MRNA, NVAX
4 days ago - CNBC Television

According to real-world data released by South Korea, one dose of COVID-19 vaccines from AstraZeneca Plc (NASDAQ: AZN) and Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) was 86.6% effective in prev...

Other stocks mentioned: AZN
4 days ago - Benzinga

Pfizer's Inc (NYSE: PFE) Hospira will recall one lot of each of the injectable hospital anesthetics bupivacaine hydrochloride (HCL) and lidocaine HCL following an investigation revealing that a portion ...

5 days ago - Benzinga

Final Trades: Marathon Petroleum, Corteva, Pfizer & more

YouTube video

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: CTVA, MPC
5 days ago - CNBC Television

Is (PFE) Outperforming Other Medical Stocks This Year?

5 days ago - Zacks Investment Research

The country's health agency credited the change to Pfizer's March trial data in adolescents.

Other stocks mentioned: BNTX
5 days ago - Forbes

Probably not, but the study could benefit another vaccine maker.

Other stocks mentioned: BNTX, MRNA
5 days ago - The Motley Fool

Ocugen may be able to handle one of the biggest challenges facing vaccine makers.

Other stocks mentioned: MRNA, OCGN
5 days ago - The Motley Fool

The Pfizer shot was 89.7% effective, and AstraZeneca was 86% effective in preventing infections among people over-60 after a single dose, according to South Korean officials.

Other stocks mentioned: AZN
5 days ago - Forbes

FDA to authorize Pfizer Covid vaccine for 12-15 year olds by next week

YouTube video

Meg Tirrell joins 'The News with Shepard Smith' to report what health experts say about vaccinating kids to help prevent Covid-19 transmission.

Other stocks mentioned: BNTX
5 days ago - CNBC Television

Pfizer (PFE) closed at $39.95 in the latest trading session, marking a +0.3% move from the prior day.

5 days ago - Zacks Investment Research

Before the market opened on May 4, Pfizer Inc. ( PFE , Financial) released its earnings results for the first quarter of 2021.

5 days ago - GuruFocus

FDA set to approve Pfizer vaccine for 12-15 year olds: RPT

YouTube video

Yahoo Finance's Adam Shapiro and Anjalee Khemlani discuss coronavirus vaccinations for 12-15 year olds. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwH...

Other stocks mentioned: BNTX
5 days ago - Yahoo Finance

Pfizer CEO: No variant identified so far that escapes our vaccine protection

YouTube video

CNBC's Kelly Evans and Meg Tirrell talk about what's next for the Pfizer and BioNTech Covid vaccine with Pfizer CEO Albert Bourla.

Other stocks mentioned: BNTX
5 days ago - CNBC Television

Pfizer Inc.'s ( PFE , Financial) Covid-19 vaccine is poised to knock AbbVie Inc.'s ( ABBV , Financial) Humira off the top perch and become the best-selling medication in pharmaceutical industry history.

Other stocks mentioned: BNTX
5 days ago - GuruFocus

Benzinga's Stock Wars series matches up two leaders in a major industry sector, with the goal of letting readers decide which company is the better investment. In this week's installment, we take a look...

Other stocks mentioned: AZN
6 days ago - Benzinga

Pfizer Inc (NYSE: PFE) has paused enrollment in a pivotal trial of its anti-BCMA bispecific antibody after seeing three cases of peripheral neuropathy in an earlier-stage study. In February, Pfizer took...

6 days ago - Benzinga

Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021.

Other stocks mentioned: BNTX
6 days ago - Zacks Investment Research

Mikael Dolsten, Pfizer's chief scientific officer, said it makes sense to start with those most susceptible to Covid.

6 days ago - CNBC

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brand... [Read more...]

Industry
Drug Manufacturers-General
Founded
1849
CEO
Albert Bourla
Employees
78,500
Stock Exchange
NYSE
Ticker Symbol
PFE
Full Company Profile

Financial Performance

In 2020, Pfizer's revenue was $41.91 billion, an increase of 1.79% compared to the previous year's $41.17 billion. Earnings were $9.62 billion, a decrease of -40.91%.

Financial Statements

Analyst Forecasts

According to 21 analysts, the average rating for Pfizer stock is "Buy." The 12-month stock price forecast is 41.99, which is an increase of 4.70% from the latest price.

Price Target
$41.99
(4.70% upside)
Analyst Consensus: Buy